Home › Research › Treatments
Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status
Rohatgi S, Younan CM, Martinez Imbett RE, Ford JN, Wleklinski M, Zhu S, Romero J.. Cureus, 2026-08-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Amyloid-related imaging abnormalities (ARIAs) are among the most important safety considerations during lecanemab treatment for Alzheimer's disease (AD). Although APOE ε4 carrier status is a recognized ARIA risk factor, the relationship between ARIAs and routine demographic and clinical characteristics in real-world practice remains incompletely characterized. This study evaluated demographic, vascular comorbidity, and APOE genotype characteristics among patients treated with lecanemab, stratified by ARIA status. Methodology We conducted a retrospective cohort study of patients with AD treated with lecanemab at a single academic institution from December 4, 2023, to October 28, 2025. Of 324 identified patients, 318 were included in the primary analysis. Demographic and clinical variables were extracted from the electronic health record. ARIA status and subtype were determined from clinical MRI interpretations by board-certified neuroradiologists. Patients were stratified by presence and type of ARIA development during treatment. Results Among 318 included patients, 98 (30.8%) developed ARIA and 220 (69.2%) did not. Among ARIA-positive patients, nine (9.2%) had ARIA-E only, 50 (51.0%) had ARIA-H only, and 39 (39.8%) had mixed ARIA-E/H. Age was similar between ARIA-positive and ARIA-negative patients (74.4 vs. 73.6 years; p = 0.437). ARIAs occurred in 33.9% of female patients and 26.8% of male patients (p = 0.218), and in 52.9% of non-White patients and 29.6% of White non-Hispanic patients (p = 0.078). Hypertension, hyperlipidemia, and diabetes were not associated with ARIA. APOE ε4 carriers had a higher incidence of ARIA than non-carriers (35.3% vs. 22.8%; p = 0.029), although differences across individual APOE genotypes did not reach statistical significance (p = 0.135). Conclusions In this real-world cohort of patients treated with lecanemab, ARIAs occurred in nearly one-third of patients. APOE ε4 carrier status was the only evaluated demographic, clinical, or genetic variable significantly associated with ARIAs. Sex- and race/ethnicity-related differences were exploratory and require validation in larger, more diverse prospective cohorts. These findings support genotype-informed ARIA surveillance while emphasizing the need for broader representation in studies of anti-amyloid therapy safety.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rohatgi, S., Younan, C. M., Martinez Imbett, R. E., Ford, J. N., Wleklinski, M., Zhu, S., et al. (2026). Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. Cureus. https://doi.org/10.7759/cureus.114472
Vancouver
Rohatgi S, Younan CM, Martinez Imbett RE, Ford JN, Wleklinski M, Zhu S, et al. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. Cureus. 2026. doi:10.7759/cureus.114472. PMID: 42732414.
BibTeX
@article{rohatgi2026-42732414,
author = {Rohatgi, S. and Younan, C. M. and Martinez Imbett, R. E. and Ford, J. N. and Wleklinski, M. and Zhu, S. and Romero, J.},
title = {{Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status}},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.114472},
pmid = {42732414},
url = {https://doi.org/10.7759/cureus.114472}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Among 318 included patients, 98 (30.8%) developed ARIA and 220 (69.2%) did not.
- Hypertension, hyperlipidemia, and diabetes were not associated with ARIA.
- APOE ε4 carrier status was the only evaluated demographic, clinical, or genetic variable significantly associated with ARIAs.
- These findings support genotype-informed ARIA surveillance while emphasizing the need for broader representation in studies of anti-amyloid therapy safety.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Effect size30.8%; 69.2%; 9.2%
- Evidence strengthModerate
How this study scored 66/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 38 of the 58 points we could judge it on, which is 66 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cureus) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42732414) |
| Free to read | 2 / 2 | Free to read |
| Points | 38 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 38 of the 58 points we could judge it on is 66 out of 100. |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “clinical-characteristics”
4 studies in the library carry the topic tag “clinical-characteristics”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.